Skip navigation

Proactive Strategies for Managing High-Risk Areas and Aligning Compliance with Business Innovation

March 12-13, 2019
  • Shanghai, China

Rapidly evolving global regulations are deeply affecting business operations in Asia. With the U.S.,UK and local Asian regulatory bodies increasing their ABAC enforcements, multinational life sciences companies must be more attentive than ever. Compliance professionals are tasked with building and maintaining effective compliance programs to meet these multi-jurisdictional requirements while still aligning with the needs of the business.

Backed by 20 years of global compliance programming and education... CBI & UBM’s Pharmaceutical Compliance Congress (PCC) Asia is the only event for compliance teams, providing novel approaches and advanced strategies for this quickly transforming regulatory landscape. This fully-packed two-day forum provides the ideal opportunity for professionals to benchmark, exchange ideas and learn about the latest laws and regulations surrounding bribery and corruption, HCP engagement, transparency, data privacy, competition, intellectual property and more.

Featuring in-depth content and insights around the most important compliance issues in China, South Korea, Japan, Indonesia, India, Thailand, Vietnam, Malaysia, the Philippines and Australia.

Explore the Top Risks and Best Practices
for Compliance Executives, including:

  • Anti-Bribery and Anti-Corruption
  • Third-Party Risk Management
  • Competition Law
  • Ethics and Compliance in Business Decision-Making
  • Data Analytics
  • HCP Sponsorships
  • Transparency Reporting
  • Drug Promotion Guidelines
  • Patient Assistance

Previous Attendee Acclaim:

CBI always provides insightful speakers who share their worldly experience on important healthcare topics.

Senior Director, Compliance, GlaxoSmithKline

This is a terrific opportunity to benchmark practices.

VP and CCO, Haemonetics Corporation